|Awarded On||August 18, 2021|
|Title||Therapeutic inhibition of cholangiocarcinoma progression by targeting tumor-lymphatic crosstalk|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Texas A&M University System Health Science Center|
|Principal Investigator/Program Director||Sanjukta Chakraborty|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
*Pending contract negotiation
Cancer metastasis accounts for 90% of cancer related deaths. Presence of tumor cells in the lymph nodes indicates poor patient survival and tumor spread that eludes current therapies. The factors that control the spread of tumor cells via the lymphatic system to lymph nodes and other organs such as the liver and lungs is not very well understood and remains a hurdle to the development of targeted clinical interventions for many types of cancers. Cancer of the liver has a high incidence in Texas. In fact, cholangiocarcinoma (CCA) is an aggressive cancer of the liver bile ducts that is increasing in incidence in Texas. CCA is often detected at late stages limiting surgical options leaving pat...